Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Brenipatide in Moderate-to-Severe COPD
jRCT2031260413Phase 2Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial of brenipatide in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in pre-bronchodilator FEV1. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
brenipatide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031260413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260413.